AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again

Nine months after filing their Enhertu follow-up Dato-DXd with the FDA, Daiichi Sankyo and its antibody-drug conjugate (ADC) partner AstraZeneca have taken the agency’s advice and pulled their lung cancer application to try their luck in a related indication.